749 related articles for article (PubMed ID: 32105817)
1. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
2. Transcytosis-enabled active extravasation of tumor nanomedicine.
Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
[TBL] [Abstract][Full Text] [Related]
3. Transcytosis of Nanomedicine for Tumor Penetration.
Liu Y; Huo Y; Yao L; Xu Y; Meng F; Li H; Sun K; Zhou G; Kohane DS; Tao K
Nano Lett; 2019 Nov; 19(11):8010-8020. PubMed ID: 31639306
[TBL] [Abstract][Full Text] [Related]
4. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
5. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
7. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
8. Polysaccharide-based nanocarriers for efficient transvascular drug delivery.
Zhang M; Ma H; Wang X; Yu B; Cong H; Shen Y
J Control Release; 2023 Feb; 354():167-187. PubMed ID: 36581260
[TBL] [Abstract][Full Text] [Related]
9. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation.
Ikeda-Imafuku M; Wang LL; Rodrigues D; Shaha S; Zhao Z; Mitragotri S
J Control Release; 2022 May; 345():512-536. PubMed ID: 35337939
[TBL] [Abstract][Full Text] [Related]
10. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
11. Antibody-activated trans-endothelial delivery of mesoporous organosilica nanomedicine augments tumor extravasation and anti-cancer immunotherapy.
Huang T; Li S; Fang J; Li F; Tu S
Bioact Mater; 2021 Jul; 6(7):2158-2172. PubMed ID: 33511314
[TBL] [Abstract][Full Text] [Related]
12. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
13. Transcytosis-Inducing Multifunctional Albumin Nanomedicines with Deep Penetration Ability for Image-Guided Solid Tumor Treatment.
Lee H; Park B; Lee J; Kang Y; Han M; Lee J; Kim C; Kim WJ
Small; 2023 Dec; 19(50):e2303668. PubMed ID: 37612796
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
15. Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery.
Zhang B; Hu Y; Pang Z
Front Pharmacol; 2017; 8():952. PubMed ID: 29311946
[TBL] [Abstract][Full Text] [Related]
16. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
[TBL] [Abstract][Full Text] [Related]
17. Tumor Abnormality-Oriented Nanomedicine Design.
Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
[TBL] [Abstract][Full Text] [Related]
18. High-resolution 3D visualization of nanomedicine distribution in tumors.
Moss JI; Barjat H; Emmas SA; Strittmatter N; Maynard J; Goodwin RJA; Storm G; Lammers T; Puri S; Ashford MB; Barry ST
Theranostics; 2020; 10(2):880-897. PubMed ID: 31903157
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy.
Xu X; Wu Y; Qian X; Wang Y; Wang J; Li J; Li Y; Zhang Z
Adv Healthc Mater; 2022 Jan; 11(1):e2101428. PubMed ID: 34706400
[TBL] [Abstract][Full Text] [Related]
20. [The development of novel tumor targeting delivery strategy].
Gao HL; Jiang XG
Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
